Company intelligence / Profile preview

ICE Pharma

Ownership: Private
Employees: ~1500
Development stage: Commercial

Overview

ICE Pharma is a leading global producer of bile acid derivatives, especially Ursodeoxycholic Acid (UDCA), with an integrated manufacturing network serving over 50 countries. The company offers APIs, finished dosage forms, excipients, contract manufacturing services, and branded products across pharmaceutical, nutraceuticals, and cosmetics markets. It has more than 70 years of experience and operates five R&D centers worldwide. No clinical trial results are reported as the company focuses on manufacturing rather than drug development.

Therapeutic areas: Gastroenterology
Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

ursodeoxycholic acid

Commercial

Indications: primary biliary cholangitis (PBC), Gallstones

Beyond the preview

Go deeper on ICE Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICE Pharma.

Explore the full profile